Antineoplastic activity of cannabinoids.
Lewis lung adenocarcinoma growth was retarded by the oral administration of delta9-tetrahydrocannabinol (delta9-THC), delta8-tetrahydrocannabinol (delta8-THC), and cannabinol (CBN), but not cannabidiol (CBD). Animals treated for 10 consecutive days with delta9-THC, beginning the day after tumor implantation, demonstrated a dose-dependent action of retarded tumor growth. Mice treated for 20 consecutive days with delta8-THC and CBN had reduced primary tumor size. CBD showed no inhibitory effect on tumor growth at 14, 21, or 28 days. Delta9-THC, delta8-THC, and CBN increased the mean survival time (36% at 100 mg/kg, 25% at 200 mg/kg, and 27% at 50 mg/kg, respectively), whereas CBD did not. Delta9-THC administered orally daily until death in doses of 50, 100, or 200 mg/kg did not increase the life-spans of (C57BL/6 times DBA/2)F1 (BDF1) mice hosting the L1210 murine leukemia. However, delta9-THC administered daily for 10 days significantly inhibited Friend leukemia virus-induced splenomegaly by 71% at 200 mg/kg as compared to 90.2% for actinomycin D. Experiments with bone marrow and isolated Lewis lung cells incubated in vitro with delta9-THC and delta8-THC showed a dose-dependent (10(-4)-10(-7)) inhibition (80-20%, respectively) of tritiated thymidine and 14C-uridine uptake into these cells. CBD was active only in high concentrations (10(-4)).
D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents; D001853:Bone Marrow / Q000378:metabolism; D001854:Bone Marrow Cells; D002185:Cannabidiol / Q000627:therapeutic use; D002188:Cannabis / Q000008:administration & dosage / Q000627:therapeutic use*; D003609:Dactinomycin / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D013759:Dronabinol / Q000494:pharmacology / Q000627:therapeutic use; D005622:Friend murine leukemia virus; D066298:In Vitro Techniques; D007939:Leukemia L1210 / Q000188:drug therapy; D008175:Lung Neoplasms / Q000188:drug therapy / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D008517:Phytotherapy; D013163:Splenomegaly / Q000188:drug therapy / Q000209:etiology; D013936:Thymidine / Q000378:metabolism; D014529:Uridine / Q000378:metabolism
D000970:Antineoplastic Agents; D002185:Cannabidiol; D003609:Dactinomycin; D013759:Dronabinol; D013936:Thymidine; D014529:Uridine